UCB files for Cimzia RA approval in Europe

UCB is taking its case to make Cimzia the first PEGylated anti-TNF biologic available to rheumatoid arthritis patients in front of the European Medicines Agency. Recently approved for Crohn's, Cimzia is one of the most closely watched RA therapies in late-stage development. And UCB has gathered data on the responses of 2,300 patients in late-stage trials.

"Along with a fast onset of action, Cimzia has been shown to rapidly reduce the rate of progression of joint damage and to improve measurements of patients' physical function," said Olav Hellebo, president of inflammation operations for UCB. "With millions of people suffering from rheumatoid arthritis across the globe, Cimzia, when approved, will provide a new and effective treatment option for this debilitating condition."

- read the UCB release

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.